Article

The cell-essentiality of KAT7 in acute myeloid leukemia

2020-01-01

Abstract excerpt

Acute myeloid leukemia (AML) is an aggressive hematopoietic malignancy, characterized by the uncontrolled proliferation and differentiation arrest of myeloid progenitors. Chemotherapy has been the front-line treatment for decades and cure remains elusive for the majority of AML patients. Genome-wide CRISPR-Cas9 screens have previously identified KAT7 as an AML-specific cell-essential gene and therefore may represe...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 23a805e7-0ff5-5e61-af7c-3e9a40162861
DOI: 10.17863/cam.47558

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

The cell-essentiality of KAT7 in acute myeloid leukemiaDOI 10.17863/cam.47558Read

KAT7 is a therapeutic vulnerability of <i>MLL</i> -rearranged acute myeloid leukemiaSemantic proximity Read

KAT7 is a genetic vulnerability of acute myeloid leukemias driven by MLL rearrangements.Semantic proximity Read

A therapeutically targetable NOTCH1-SIRT1-KAT7 axis in T-cell LeukemiaSemantic proximity Read

KATs in the MYST: A New Therapeutic Vulnerability for SETBP1-Mutated Myeloid Malignancies.Semantic proximity Read

Catalytic Inhibition of KAT6/KAT7 Enhances the Efficacy and Overcomes Primary and Acquired Resistance to Menin Inhibitors in MLL LeukemiaSemantic proximity Read

Regulation of KAT6 Acetyltransferases and Their Roles in Cell Cycle Progression, Stem Cell Maintenance, and Human Disease.Semantic proximity Read

HDAC7 is a potential therapeutic target in acute erythroid leukemiaSemantic proximity Read

Contributions of transcriptional noise to leukaemia evolution: KAT2A as a case-study.Semantic proximity Read

Catalytic inhibition of KAT6/KAT7 enhances the efficacy and overcomes primary and acquired resistance to Menin inhibitors in MLL leukaemiaSemantic proximity Read

The small inhibitor WM-1119 effectively targets KAT6A-rearranged AML, but not KMT2A-rearranged AML, despite shared KAT6 genetic dependencySemantic proximity Read

Disrupting a Convergent Acetylation Circuit Collapses Leukemic Identity Across AML SubtypesSemantic proximity Read

MECOM is a master repressor of myeloid differentiation through dose control of <i>CEBPA</i> in acute myeloid leukemiaSemantic proximity Read